Olmesartan medoxomil: In children and adolescents with hypertension

Drugs

Volumn 70, Issue 18, 2010, Pages 2439-2447

  Muir, Victoria J ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Adolescents; Children; Hypertension; Olmesartan medoxomil, general

Indexed keywords

CYTOCHROME P450; OLMESARTAN; PLACEBO;

ABNORMAL SENSATION; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COHORT ANALYSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INSOMNIA; KIDNEY DISEASE; LOW DRUG DOSE; METABOLIC DISORDER; MONOTHERAPY; NONHUMAN; POTASSIUM BLOOD LEVEL; RELAPSE; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; CHILD; HUMANS; HYPERTENSION; IMIDAZOLES; TETRAZOLES;

EID: 78649920426     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11206310-000000000-00000     Document Type: Article

References (25)

1. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA 2007 Aug 22; 298 (8): 874-9.
2. Ostchega Y, Carroll M, Prineas RJ, et al. Trends of elevated blood pressure among children and adolescents: data from the National Health and Nutrition Examination Survey 1988-2006. Am J Hypertens 2009 Jan; 22 (1): 59-67.
3. Din-Dzietham R, Liu Y, Bielo MV, et al. High blood pres- sure trends in children and adolescents in national surveys, 1963 to 2002. Circulation 2007 Sep 25; 116 (13): 1488-96.
4. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114 (2): 555-76.
5. Robinson RF, Nahata MC, Batisky DL, et al. Pharmaco- logic treatment of chronic pediatric hypertension. Paediatr Drugs 2005; 7 (1): 27-40.
6. Flynn JT. Pediatric hypertension: recent trends and accom- plishments, future challenges. Am J Hypertens 2008; 21 (6): 605-12.
7. Flynn JT, Daniels SR. Pharmacologic treatment of hy- pertension in children and adolescents. J Pediatr 2006; 149 (6): 746-54.
8. Daiichi Sankyo Inc. Benicar® (olmesartan medomoxil) ta- blets: US prescribing information [online]. Available from URL: http://www.benicar.com/ pdf/prescribing-information. pdf [Accessed 2010 Aug 11].
9. Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs 2008; 68 (9): 1239-72.
10. Mire DE, Silfani TN, Pugsley MK. A review of the struc- tural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005 Nov; 46 (5): 585-93.
11. Warner GT, Jarvis B. Olmesartan medoxomil [published erratum appears in Drugs 2002; 62 (13): 1852]. Drugs 2002; 62(9): 1345-53; discussion 1354-6.
12. Mizuno M, Sada T, Ikeda M, et al. Pharmacology of CS- 866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995 Oct 16; 285 (2): 181-8.
13. Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens 2007 Aug; 20 (8): 907-16.
14. Resnick LM, Catanzaro D, Sealey JE, et al. Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system. Am J Hypertens 2004 Mar; 17 (3): 203-8.
15. Hasler C, Nussberger J, Maillard M, et al. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther 2005 Nov; 78 (5): 501-7.
16. Puchler K, Nussberger J, Laeis P, et al. Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. J Hypertens 1997 Dec; 15 (12 Pt 2): 1809-12.
17. Daiichi Sankyo Inc. Olmesartan pediatric pharmacokinetic (PK) study [ClinicalTrials.gov identifier NCT00151814] US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Aug 10].
18. US Food and Drug Administration. Olmesartan medoxomil (Benicar®) clinical pharmacology review [online]. Available from URL: http://www.fda.gov/ downloads/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/ UCM201697.pdf [Accessed 2010 Jul 12].
19. Schwocho LR, Masonson HN. Pharmacokinetics of CS- 866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001 May; 41 (5): 515-27.
20. Laeis P, Puchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl 2001 Jun; 19 (1): S21-32.
21. Rohatagi S, Lee J, Shenouda M, et al. Pharmacokinetics of amlodipine and olmesartan after administration of amlo- dipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. J Clin Pharmacol 2008 Nov; 48 (11): 1309-22.
22. Bolbrinker J, Huber M, Scholze J, et al. Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. Fundam Clin Pharmacol 2009 Dec; 23 (6): 767-74.
23. Kreutz R, Bolbrinker J, Huber M. Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Clin Drug Investig 2006; 26 (1): 29-34.
24. Hazan L, Hernandez Rodriguez OA, Bhorat AE, et al. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension 2010 Jun; 55 (6): 1323-30.
25. US Food and Drug Administration. Benicar® (olmesartan medoxomil) tablets clinical review [online]. Available from URL: http://www.fda.gov/ downloads/Drugs/Development ApprovalProcess/DevelopmentResources/UCM201695. pdf [Accessed 2010 Jul 12]